The Global Acute Otitis Media Treatment Market, By Drug Type (Antibiotics, Nonsteroidal anti-Inflammatory Drug, Analgesic, and Anaesthetic), By Formulation (Oral and Topical), By Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 2,043.3 million in 2016 and is projected to exhibit a CAGR of 5.1% over the forecast period (2017 – 2025).
Increasing prevalence of acute otitis media is expected to be a major factor in growth of acute otitis media treatment market. According to an article published in PLOS ONE Journal in 2012, acute otitis media incidence rate is about 10.9% and around 709 million people suffer from this diseases each year. Of these, children under the age of 5 account for around 51%. Increasing prevalence of acute otitis media among children is expected to lead to increasing demand for treatment.
Browse 36 Market Data Tables and 42 Figures spread through 178 Pages and in-depth TOC on Acute Otitis Media Treatment Market by Drug Type (Antibiotics, Nonsteroidal anti-Inflammatory drug, Analgesic, and Anaesthetic), By Formulation (Oral, and Topical), By End User (Hospitals, Retail pharmacies, and Online pharmacies) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025.
To know the latest trends and insights prevalent in the Acute Otitis Media Treatment Market, click the link below:
Key players in the acute otitis media treatment market are focusing on launching multiple products. Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC launched OTOVEL (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) and the solution indicated for the treatment of acute otitis media. Increasing product approvals is another factor expected to aid in growth of the market. For instance, in 2017, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on GlaxoSmithKline plc. new four-dose vial of Synflorix pneumococcal vaccine indicated for active immunisation against acute otitis media. In 2013, Pfizer Inc. received European approval to expand use of its Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine) for adults aged 18 to 49 years for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumonia. In 2015, Otonomy, Inc. received U.S. Food and Drug Administration (FDA) approval for its OTIPRIO (ciprofloxacin otic suspension) used in the treatment of AOM.
Key Takeaways of the Acute Otitis Media Treatment Market: